WHO Issues New Clinical Advice On Treating Covid-19 Patients

Geneva : The World Health Organization (WHO) issued fresh clinical advice on Tuesday for treating COVID-19 patients, including those displaying persistent symptoms after recovery, and also said it advised using low-dose anti-coagulants to prevent blood clots.

“The other things in the guidance that are new are that COVID-19 patients at home should have the use of pulse oximetry, that’s measuring the oxygen levels, so you can identify whether somewhat at home is deteriorating and would be better off having hospital care,” WHO spokeswoman Margaret Harris told a U.N. briefing in Geneva.

The WHO advised clinicians to put patients into the awake prone position, on their front, shown to improve the oxygen flow, she said.

“Also we recommend, we suggest the use, of low-dose anti-coagulents to prevent blood clots forming in blood vessels. We suggest the use of lower doses rather than higher doses because higher doses may lead to other problems,” Harris said.

She added that a WHO-led team of independent experts, currently in the central Chinese city of Wuhan where the first human cases were detected in December 2019, is due to leave quarantine in the next two days to pursue its work with Chinese researchers on the virus origins.

She declined to commment on reports of delays in roll-out of vaccines in the European Union. She said she had no specific data and the WHO’s priority was for health workers in all countries to be vaccinated in the first 100 days of the year.

AstraZeneca, which developed its shot with Oxford University, told the EU on Friday it could not meet agreed supply targets up to the end of March.

Related Posts

  • Pharma
  • June 30, 2025
  • 74 views
JB Chemicals shares tank 7% as Torrent Pharma acquires controlling stake worth Rs 25,689 crore

Shares of JB Chemicals and Pharmaceuticals nosedived as much as 7 percent to Rs 1,673 on June 30 after Torrent Pharmaceuticals acquired a controlling stake in the company from global…

  • Pharma
  • June 27, 2025
  • 205 views
Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech International Ltd and GSK plc on Wednesday said they will reduce the price of the world’s first malaria vaccine for children ‘RTS,S’ developed by GSK, PATH and partners,…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

JB Chemicals shares tank 7% as Torrent Pharma acquires controlling stake worth Rs 25,689 crore

JB Chemicals shares tank 7% as Torrent Pharma acquires controlling stake worth Rs 25,689 crore

Amrita Hospital becomes a cut above rest in Cancer Care in India

Amrita Hospital becomes a cut above rest in Cancer Care in India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

MedTech Zone AMTZ Puts Vizag on the Science Map of India

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028

Bharat Biotech, GSK to cut malaria vaccine price by more than half by 2028